1. Home
  2. LIDR vs TCRX Comparison

LIDR vs TCRX Comparison

Compare LIDR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AEye Inc.

LIDR

AEye Inc.

N/A

Current Price

$1.17

Market Cap

56.5M

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

N/A

Current Price

$0.31

Market Cap

49.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LIDR
TCRX
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.5M
49.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
LIDR
TCRX
Price
$1.17
$0.31
Analyst Decision
Strong Buy
Hold
Analyst Count
2
5
Target Price
★ $4.75
$1.00
AVG Volume (30 Days)
980.4K
★ 1.3M
Earning Date
11-05-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 12.28
EPS
N/A
★ N/A
Revenue
$233,000.00
★ $10,325,000.00
Revenue This Year
$952.79
N/A
Revenue Next Year
$778.52
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
15.35
★ 266.65
52 Week Low
$1.01
$0.29
52 Week High
$4.00
$2.57

Technical Indicators

Market Signals
Indicator
LIDR
TCRX
Relative Strength Index (RSI) 44.17 28.71
Support Level $1.16 $0.29
Resistance Level $1.38 $0.37
Average True Range (ATR) 0.04 0.03
MACD -0.00 0.02
Stochastic Oscillator 25.00 39.63

Price Performance

Historical Comparison
LIDR
TCRX

About LIDR AEye Inc.

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: